US 6,548,527 B2Granted

Treatments for immune-mediated ear disorders

AssigneeThe General Hospital Corporation

InventorsMahboob U. Rahman, Dennis S. Poe, Hyon K. Choi

Life of this patent

Estimating the term…

Abstract

Disclosed herein are methods for treating immune-mediated ear disorders, such as IMCVDs, or their symptoms, involving administration of a therapeutically-effective amount of a TNF antagonist, such as etanercept or infliximab, or a therapeutically-effective amount of a pyrimidine synthesis inhibitor, such as leflunomide.

Claims13

Dependent claims

A method of treating a mammal with an immune-mediated ear disorder, said method comprising administering to said mammal a therapeutically-effective amount of a TNF antagonist.

Dependencies are inferred from the claim text.

Facts

Application: 09/818,411Filed 27 Mar 2001 · us provisional application
Priority: 27 Mar 2000
Published: US 2002/0044920 A118 Apr 2002
Granted: 15 Apr 2003
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 31/275
Medicinal preparations containing organic active ingredients: nitriles; Isonitriles
A61K 38/1793
Receptors; Cell surface antigens; Cell surface determinants: for cytokines; for lymphokines; for interferons

Family

Application60/192,299Us provisional application · filed 27 Mar 2000
US 2002/0044920 A1Pre-grant publication · published 18 Apr 2002
US 6,548,527 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results